Treatment beyond progression? Zenocutuzumab data could shift standards in NRG1+ pancreatic cancer
Find out how zenocutuzumab could change treatment strategies in NRG1+ pancreatic cancer after progression. Explore new ASCO GI 2026 data today.
Pharma & Biotech
Pharma & Biotech
How Indivumed’s biospecimen strategy is powering functional tumor model development
Indivumed GmbH and the Wilmot Cancer Institute at the University of Rochester Medical Center have expanded their collaboration to accelerate the development of patient-derived tumor models and AI-informed therapeutic discovery for solid tumors with high unmet clinical need. What this collaboration changes for the cancer model ecosystem The expansion of the Indivumed and University of
Pharma & Biotech
Can Diakonos Oncology’s DOC1021 reawaken immune response in refractory melanoma?
Diakonos Oncology Corporation has received over $7 million from the Cancer Prevention and Research Institute of Texas to initiate a Phase 1/2 clinical trial of its double-loaded dendritic cell therapy, DOC1021, in patients with refractory melanoma. The grant places the investigational therapy into its third solid tumor indication and signals rising institutional interest in immune-based